Regeneron Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Regeneron Pharmaceuticals, Inc. (Regeneron or the Company), and actual events or results may differ materially from these forward-looking statements. Words such as anticipate, expect,
intend, plan, believe, seek, estimate, variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking
statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by
Regeneron and/or its collaborators or licensees (collectively, Regenerons Products) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, Regenerons Product
Candidates) and research and clinical programs now underway or planned, such as the research programs with Intellia Therapeutics, Inc. to develop in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases
discussed in this press release; the potential for any license, collaboration, or supply agreement, including Regenerons agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), as well as Regenerons
collaboration with Intellia discussed in this press release, to be cancelled or terminated; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (including those
conducted as part of the collaboration with Intellia discussed in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the
potential of utilizing for therapeutic purposes Regenerons novel adeno-associated virus (AAV) vectors and delivery systems and Intellias proprietary Nme2 CRISPR/Cas9 (Nme2Cas9) systems adapted for viral vector delivery as discussed in
this press release; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regenerons Product Candidates and new indications for Regenerons Products; uncertainty of the utilization, market acceptance,
and commercial success of Regenerons Products and Regenerons Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary, including those discussed or referenced in this press
release) on any of the foregoing or any potential regulatory approval of Regenerons Products and Regenerons Product Candidates; the ability of Regenerons collaborators, licensees, suppliers, or other third parties (as applicable)
to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regenerons Products and Regenerons Product Candidates; the ability of Regeneron to manage supply chains for multiple products and
product candidates; safety issues resulting from the administration of Regenerons Products and Regenerons Product Candidates in patients, including serious complications or side effects in connection with the use of Regenerons
Products and Regenerons Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regenerons ability to continue to develop or commercialize
Regenerons Products and Regenerons Product Candidates; ongoing regulatory obligations and oversight impacting Regenerons Products, research and clinical programs, and business, including those relating to patient privacy; the
availability and extent of reimbursement of Regenerons Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government
programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than,
Regenerons Products and Regenerons Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the
assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regenerons business; and risks associated with
intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA®
(aflibercept) Injection and REGEN-COV® (casirivimab and imdevimab)), other litigation and other proceedings and government investigations relating to
the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regenerons business, prospects, operating results, and financial condition. A more complete
description of these and other material risks can be found in Regenerons filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2022 and
its Form 10-Q for the quarterly period ended June 30, 2023. Any forward-looking statements are made based on managements current beliefs and judgment, and the reader is cautioned not to rely on any
forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new
information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important
information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regenerons media and investor relations website
(https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).
|
|
|
Page 3 of 5 |
|
intelliatx.com |